One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Is Histopathology Deep Learning Artificial Intelligence the Future of Precision Oncology?
doi : 10.1200/JCO-24-01271
2024, Volume 42 (30)
Navigating Hormone Therapy in Postmenopausal Women: Balancing Symptom Relief With Cancer Risk
doi : 10.1200/JCO-24-01352
Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer
doi : 10.1200/JCO.24.00372
Estrogen Plus Progestin and Colorectal Cancer: Long-Term Findings From the Women's Health Initiative Randomized Clinical Trial
doi : 10.1200/JCO.23.02092
Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials
doi : 10.1200/JCO.23.01918
Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides
doi : 10.1200/JCO.23.02641
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial
doi : 10.1200/JCO.23.01995
Randomized Controlled Trial of a Nurse-Led Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer
doi : 10.1200/JCO.24.00048
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
doi : 10.1200/JCO.23.02786
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study
doi : 10.1200/JCO.24.01001
Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)
doi : 10.1200/JCO.23.02668
Social Genomic Determinants of Health: Understanding the Molecular Pathways by Which Neighborhood Disadvantage Affects Cancer Outcomes
doi : 10.1200/JCO.23.02780
How to Test HER2 for Predicting Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer? Evidence From the Secondary Analysis of Biomarkers of CALGB/SWOG 80405
doi : 10.1200/JCO.24.00805
Erratum: Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial
doi : 10.1200/JCO-24-01883
Erratum: Surveillance Imaging After Curative-Intent Treatment for Cancer: Benefits, Harms, and Evidence
doi : 10.1200/JCO-24-01942
